ALZN NASDAQ
Alzamend Neuro Inc
1W: -16.5%
1M: -39.3%
3M: -15.3%
YTD: -41.6%
1Y: -52.4%
3Y: -99.6%
5Y: -100.0%
$1.13
-0.01 (-0.88%)
After Hours: $1.15 (+0.02, +1.77%)
Weekly Expected Move ±14.2%
$1
$1
$1
$1
$1
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' -27.54.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.5M
52W Range0.84-2.68
Volume8,812
Avg Volume137,945
Beta0.19
Dividend—
Analyst Ratings
Company Info
CEOStephan Jackman
Employees6
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-15
Websitealzamend.com
3480 Peachtree Road NE
Atlanta, GA 30326
US
Atlanta, GA 30326
US
844 722 6333
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Latest News
Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?
Alzamend Neuro regains Nasdaq compliance
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 32.6% in March
FY2026 EPS Estimates for Alzamend Neuro Reduced by Analyst
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| AULT MILTON C III | S-Sale | 2,000 | $1.56 | 2026-08-26 |
| Hyperscale Data, Inc | A-Award | 7,500 | — | 2026-07-31 |
| AULT MILTON C III | A-Award | 7,500 | — | 2026-07-31 |
| Jackman Stephan | A-Award | 450,000 | $2.33 | 2026-04-17 |
| Katzoff David J | A-Award | 300,000 | $2.33 | 2026-04-17 |